Table 1.
Group characteristics at baseline
| Demographic and disease characteristics of patient cohort |
STN (n = 20) | GPi (n = 22) | t test | P |
|---|---|---|---|---|
| Age | 61.3 (9.0) | 61.3 (5.5) | 0.01 | 0.99 |
| Sex (M/F) | 14/6 | 16/6 | ||
| Disease duration (months) | 162.8 (46.6) | 148.3 (43.0) | 1.05 | 0.30 |
| Side of surgery (R/L) | 7/13 | 9/13 | ||
| UPDRS-III “on” | 21.5 (7.3) | 22.3 (8.3) | −0.34 | 0.74 |
| UPDRS-III “off” | 43.8 (10.6) | 41.8 (10.0) | 0.64 | 0.53 |
| LED | 935.9 (374.0) | 1,199.8 (576.9) | −1.7 | 0.09 |
| BDI-II | 10.8 (6.5) | 11.6 (6.7) | −0.41 | 0.69 |
| STAI state | 36.5 (10.9) | 35.8 (11.2) | 0.20 | 0.84 |
| STAI trait | 34.8 (10.6) | 33.5 (11.6) | 0.34 | 0.73 |
| MMSE | 28.5 (1.6) | 28.6 (1.3) | −0.41 | 0.68 |
| DRS-2 | 136.9 (7.0) | 139.2 (4.5) | −1.25 | 0.22 |
| Letter fluency (raw) | 37.9 (9.9) | 36.5 (13.5) | 0.36 | 0.72 |
| Animal fluency (raw) | 18.5 (4.5) | 19.2 (4.9) | −0.50 | 0.62 |
| PDQ-39 summary index | 34.2 (13.3) | 36.5 (15.7) | −0.52 | 0.60 |
| Mobility | 49.3 (24.5) | 48.6 (19.0) | 0.09 | 0.93 |
| ADLs | 41.9 (20.4) | 40.5 (18.2) | 0.23 | 0.82 |
| Emotional well-being | 31.9 (21.8) | 30.1 (22.4) | 0.26 | 0.80 |
| Stigma | 23.5 (20.6) | 38.7 (19.1) | −2.49 | 0.02 |
| Social support | 13.7 (16.9) | 19.7 (19.5) | −1.05 | 0.30 |
| Cognition | 31.6 (19.4) | 34.4 (25.4) | −0.40 | 0.69 |
| Communication | 32.1 (21.3) | 36.0 (21.0) | −0.60 | 0.56 |
| Discomfort | 49.6 (20.9) | 44.3 (23.2) | 0.77 | 0.45 |
M Male, F female, R right, L left, STN subthalamic nucleus, GPi globus pallidus internus, UPDRS-III Unified Parkinson Disease Rating Scale–motor portion, LED levodopa equivalent dosage, BDI-II, Beck Depression Inventory, 2nd edition, STAI Stait-Trait Anxiety Inventory, MMSE, Mini-Mental State Exam, DRS-2, Dementia Rating Scale, ADLs, activities of daily living, PDQ-39 Parkinson’s Disease Questionnaire
Values are given as the mean with the standard deviation (SD) in parenthesis